1 Dubrey SW, "The clinical features of immunoglobulin light-chain(AL)amyloidosis with heart involvement" 91 : 141-157, 1998
2 Robbers LF, "T1 mapping shows increased extracellular matrix size in the myocardium due to amyloid depositions" 5 : 423-426, 2012
3 Banypersad SM, "T1 mapping and survival in systemic light-chain amyloidosis" 36 : 244-251, 2015
4 Dispenzieri A, "Serum cardiac troponins and Nterminal pro-brain natriuretic peptide : a staging system for primary systemic amyloidosis" 22 : 3751-3757, 2004
5 Hur DJ, "Serial native T1 mapping to monitor cardiac response to treatment in light-chain amyloidosis" 9 : e004770-, 2016
6 Kumar S, "Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements" 30 : 989-995, 2012
7 Karamitsos TD, "Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis" 6 : 488-497, 2013
8 Ridouani F, "Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis" 20 : 58-, 2018
9 Aus dem Siepen F, "Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate : preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study" 104 : 640-647, 2015
10 Kristen AV, "Cardiac amyloid load : a prognostic and predictive biomarker in patients with light-chain amyloidosis" 68 : 13-24, 2016
1 Dubrey SW, "The clinical features of immunoglobulin light-chain(AL)amyloidosis with heart involvement" 91 : 141-157, 1998
2 Robbers LF, "T1 mapping shows increased extracellular matrix size in the myocardium due to amyloid depositions" 5 : 423-426, 2012
3 Banypersad SM, "T1 mapping and survival in systemic light-chain amyloidosis" 36 : 244-251, 2015
4 Dispenzieri A, "Serum cardiac troponins and Nterminal pro-brain natriuretic peptide : a staging system for primary systemic amyloidosis" 22 : 3751-3757, 2004
5 Hur DJ, "Serial native T1 mapping to monitor cardiac response to treatment in light-chain amyloidosis" 9 : e004770-, 2016
6 Kumar S, "Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements" 30 : 989-995, 2012
7 Karamitsos TD, "Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis" 6 : 488-497, 2013
8 Ridouani F, "Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis" 20 : 58-, 2018
9 Aus dem Siepen F, "Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate : preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study" 104 : 640-647, 2015
10 Kristen AV, "Cardiac amyloid load : a prognostic and predictive biomarker in patients with light-chain amyloidosis" 68 : 13-24, 2016